About Kimberly Blumenthal, MD, MSC

Watch a video about my work


Kimberly Blumenthal, MD, MSc is an Allergist/Immunologist and drug allergy researcher at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School.  She is the Co-Director of the Clinical Epidemiology Program within the Division of Rheumatology Allergy and Immunology and the Quality and Safety Officer for Allergy at the Edward P. Lawrence Center for Quality and Safety. Dr. Blumenthal performs drug allergy research that uses methods of epidemiology, informatics, economics, and decision science.  Her research is funded by the NIH/NIAID, AHRQ, and foundations, including the American Academy of Allergy, Asthma, and Immunology Foundation and CRICO, the risk management foundation.  Dr. Blumenthal is recognized nationally for having identified the morbidity and mortality associated with unverified penicillin allergy labels and creating innovative approaches to the evaluation of penicillin and cephalosporin antibiotic allergies in the hospital setting. Dr. Blumenthal has authored more than 60 peer-reviewed publications including manuscripts published in high-impact journals such as Lancet, JAMA, and the BMJ.

Dr. Blumenthal graduated from Columbia University with a BA in Economics.  She studied medicine at Yale University School of Medicine, before training at the Massachusetts General Hospital for Internal Medicine and Allergy and Immunology. She completed a Master of Science in Clinical Epidemiology at the Harvard T.H. Chan School of Public Health in 2017.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Medicine: Allergy & Clinical Immunology Unit
55 Fruit St.
Yawkey 4B
Boston, MA 02114
Phone: 617-726-3850

Medical Education

  • MD, Yale University School of Medicine
  • Residency, Massachusetts Eye and Ear***
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Allergy & Immunology, American Board of Allergy and Immunology
  • Internal Medicine, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Blumenthal's clinical research laboratory is funded by the National Institutes of Health, the American Academy of Allergy, Asthma, and Immunology, CRICO, and the MGH Executive Committee on Research.. She has authored or co-authored over 50 peer-reviewed publications related to improving the care of patients with drug allergies.  Dr. Blumenthal is Principal Investigator of the United States Drug Allergy Registry (USDAR), the first national prospective cohort of patients who receive drug allergy evaluations.  




  • Dr. Blumenthal performs epidemiology, informatics, outcomes and cost-effectiveness research in the field of drug allergy.  Her past research evaluated both true drug hypersensitivity and the clinical impact of over-reported drug allergies on patients and healthcare systems, and includes over 70 peer-reviewed manuscripts.

    As part of her post-doctoral research, she designed, implemented and evaluated a hospital-wide guideline for antibiotic prescribing for patients with a reported β-lactam antibiotic allergy at  Mass General.  After successfully demonstrating the guideline’s safety, feasibility, and positive impact on antibiotic stewardship at two institutions,  she led the implementation of this guideline throughout Mass General Brigham hospitals. 

    Dr. Blumenthal is Principal investigator of the United States Drug Allergy Registry (usdar.massgeneral.org), a longitudinal prospective cohort of patients assessed for possible drug allergy, including a possible allergy to penicillin antibiotics. 

Reviews: Comments and Ratings